Stockwinners Market Radar for September 19, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:40 EDT Cathie Wood's ARK Investment bought 970K shares of Ginkgo Bioworks today

20:37 EDT Cathie Wood's ARK Investment bought 150.5K shares of Intellia Therapeutics today

20:29 EDT Cathie Wood's ARK Investment bought 370K shares of PacBio today

20:15 EDT Zscaler COO sells $2.31M in common stock - In a regulatory filing, Zscaler disclosed that its COO Dali Rajic sold 15K shares of common stock on September 18th in a total transaction size of $2.31M.

18:46 EDT Barington Capital: Separation of Hanesbrands' Champion 'makes strategic sense' - Barington Capital Group, a fundamental, value-oriented activist investor which is a shareholder of Hanesbrands, issued the following statement regarding the company's announcement that it will explore strategic options for its global Champion business. "As we have communicated in our recent discussions with Hanesbrands' Board of Directors and management team, we believe urgent and decisive action is required to generate cash, reduce the company's debt, and create value for all shareholders," said James Mitarotonda, Chairman and CEO of Barington. Mitarotonda continued, "While we believe a separation of the Champion business makes strategic sense, it is critical that, despite recent performance, the Company achieves appropriate value for this iconic brand. We will continue to closely monitor further developments and urge Hanesbrands to rapidly pursue all opportunities to create long-term shareholder value."

18:16 EDT Planet Labs CEO buys $269.8K in common stock - In a regulatory filing, Planet Labs disclosed that its CEO William Marshall bought 100K shares of common stock on September 19th in a total transaction size of $269.8K. Shares of Planet Labs are up 5% afterhours at $2.83.

18:08 EDT Puma Biotechnology's alisertib granted orphan designation by FDA - According to a post on the FDA's website, Puma Biotechnology's alisertib was granted orphan designation in the treatment of small cell lung cancer. Reference Link

17:41 EDT Microsoft's 'Starfield' exceeds 10M players - Microsoft said its latest Xbox console exclusive "Starfield," which is also available on PC, has already surpassed 10M players, making it the biggest launch in Bethesda history. The game launched in early access in late August for special edition purchasers and launched globally on September 6. Reference Link

17:22 EDT Nano Dimension spikes higher on share repurchase plan resumption - Shares of additive electronic maker Nano Dimension are up over 7% or 18c to $2.71 per share in after-hours trading on Tuesday after the company which offers 3D printers, comprising DragonFly IV reported has received approval from the Israeli court to continue with its previously announced share repurchase plan, which initially was approved by the Israeli court in August 2022, until October 12. Yoav Stern, Chief Executive Officer of the Company, commented: "We continue to fulfill our previous promise to investors, which was temporarily held back due to the time expiration of the Israeli court approval. We thank the court again for its flexibility in extending the Repurchase Plan period. We are happy to act in a way that both improves the Company's balance sheet and benefits its shareholders." The Repurchase Plan authorizes the Company's management to repurchase American Depository Shares from time to time, in open market transactions ..The Company may repurchase all or a portion of the authorized repurchase amount. The Repurchase Plan does not obligate the Company to repurchase any specific number of the ADSs and may be suspended or terminated at any time at the Company's sole discretion.

17:08 EDT HP Enterprise creating new Hybrid Cloud business - Antonio Neri, President and CEO of Hewlett Packard Enterprise said in part in a statement on Tuesday: "I said during my first days as CEO that the enterprise of the future would be edge-centric, cloud-enabled, and data-driven. That vision from nearly six years ago has turned into strategy, then innovation, and ultimately into strong momentum for HPE and business outcomes for customers and partners in every industry. Having laid the foundation for success, we are now evolving our operating model to accelerate our execution, deliver a superior customer and partner experience, and drive growth for the company and value for our shareholders. These changes to HPE's organizational structure and executive leadership, which take effect at the start of our 2024 fiscal year on November 1 will further unify our portfolio and enhance the delivery of a true cloud experience for our customers and partners. They will enable tighter integrations that benefit our customers and partners and spark innovation. And, they position us to continue to win in the market. We are creating a new Hybrid Cloud business unit, to be led by HPE Chief Technology Officer Fidelma Russo. This business will bring together the HPE GreenLake platform with the technologies and services of HPE Storage, HPE GreenLake Cloud Services Solutions and the current Office of the CTO organization. This new group will accelerate our hybrid cloud strategy as we deliver one portfolio of storage, software, data, and cloud services on the HPE GreenLake platform." Reference Link

17:01 EDT Steelcase jumps 3% to $9.10 after Q2 earnings beat, above-consensus guide

16:53 EDT Arthur J. Gallagher signs definitive agreement to acquire Eastern Insurance - Arthur J. Gallagher & Co. (AJG) announced it has signed a definitive agreement to acquire Natick, Massachusetts-based Eastern Insurance Group, a subsidiary of Eastern Bank. The transaction is subject to regulatory approval and is expected to close during the Q4. Eastern Insurance offers comprehensive commercial property/casualty and personal lines products as well as employee benefits consulting to clients throughout the Northeast US. Tim Lodge and his team will remain in their current location under the direction of Patrick Kennedy, head of Gallagher's Northeast region retail property/casualty brokerage operations, and John Neumaier, head of Gallagher's East region employee benefits consulting and brokerage operations.

16:45 EDT Eastern Bankshares trading resumes

16:40 EDT Xbox boss says Microsoft will share 'real plans' when ready - In response to news of the leak of Microsoft documents pertaining to its video game business, Microsoft Gaming CEO Phil Spencer said on social media platform X," We've seen the conversation around old emails and documents. It is hard to see our team's work shared in this way because so much has changed and there's so much to be excited about right now, and in the future. We will share the real plans when we are ready." Reference Link

16:36 EDT Toast CEO sells $1.17M in common stock - In a regulatory filing, Toast disclosed that its CEO Christopher Comparato sold 58K shares of common stock on September 15th in a total transaction size of $1.17M.

16:35 EDT Locafy announces partnership with Australian digital marketing agency Method - Locafy Limited announced its enterprise-level partnership with Method , an Australian digital marketing agency with local-scale expertise. Founded in 2016, Method specializes in website development, SEO, social media strategy, branding, and copywriting. Method has been using Locafy's products over several years, and has grown to enterprise partner scale through an expanded client network and significant growth to date. Through this continued partnership, Method will ramp-up its deployment of Locafy's Entity-Based SEO product suite products to further supplement its growth and increase its market share. "As a digital marketing specialist, we provide our clients with a comprehensive plan to improve brands' online presences," said Method CEO, Ethan Capolingua. "Locafy's technology completes our offering suite, providing our agency with an out-of-the-box SEO solution that we can deploy for our clients to drive fast results in online search. We look forward to expanding our partnership with Locafy as we strive to gain additional share in the local-scale online marketing segment."

16:28 EDT Otonomo Technologies announces shareholder approval of Urgent.ly combination - Otonomo Technologies announced that its shareholders approved its proposed business combination with Urgent.ly, a U.S.-based provider of digital roadside and mobility assistance technology and services, at a special meeting of shareholders held yesterday. Upon closing of the transaction, which is expected to occur before the end of October, the combined company will operate under the name Urgent.ly, Inc. and its common stock is expected to be listed on Nasdaq under the ticker symbol (ULY), subject to the approval of Nasdaq.

16:24 EDT Cambridge Bancorp and Eastern Bankshares enter into definitive merger agreement - Cambridge Bancorp (CATC), the parent company of Cambridge Trust Company, and Eastern Bankshares (EBC), the stock holding company for Eastern Bank, announced they have entered into a definitive merger agreement pursuant to which Cambridge will merge with and into Eastern in an all-stock transaction valued at approximately $528M. Under the terms of the merger agreement, which has been unanimously approved by both boards of directors, each share of Cambridge common stock will be exchanged for 4.956 shares of Eastern common stock. Eastern anticipates issuing approximately 39.4 million shares of its common stock in the merger. Based upon Eastern's $13.41 per share closing price on September 18, 2023, the transaction is valued at approximately $528M and the aggregate consideration represents 114% of Cambridge's tangible book value and a 24% premium to Cambridge's thirty-day volume weighted average price. Upon closing, Denis Sheahan, Chairman, President and CEO of Cambridge, will become the CEO of Eastern and will join Eastern's Board of Directors. Eastern's President Quincy Miller will be promoted to Vice Chair, President, and COO. Both Sheahan and Miller will report directly to Bob Rivers, who will serve as Executive Chair and Chair of the Board of Directors. In addition to Sheahan, three Cambridge directors are expected to be elected to Eastern's Board of Directors in connection with the closing. The merger is expected to be completed during the Q1of 2024, subject to certain conditions, including the receipt of required regulatory approvals; and approval by Cambridge and Eastern shareholders. BofA Securities served as financial advisor and Hogan Lovells US provided legal counsel to Cambridge. J.P. Morgan Securities served as financial advisor and Nutter McClennen & Fish provided legal counsel to Eastern.

16:19 EDT Zivo Bioscience reports 'positive' results from month-long coccidiosis trial - Zivo Bioscience announced positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the company's novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statistically significant positive outcomes in the treated groups. Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billion (Re-calculating the Cost of Coccidiosis in Chickens; Blake, D., Knox, J., et al.). Products for treating coccidiosis are mostly antibiotic or ionophore-based, and no commercially significant new technology has been introduced in the past 60 years. The disease challenge used in this trial closely replicated conditions often seen in commercial broiler production facilities experiencing a coccidiosis outbreak, including commercially relevant incidence and severity of intestinal lesions, mortality, and other disease related measures. Birds treated with ZIVO's product candidate demonstrated statistically significant improvements across all measures of broiler health examined. Diseased chickens treated with elevated doses of ZIVO's product candidate exhibited reductions in disease-related effects to a level seen in healthy birds.

16:18 EDT Argan raises quarterly dividend by 20% to 30c per share - The dividend will be payable on October 31, 2023 to stockholders of record at the close of business on October 23, 2023.

16:17 EDT Eastern Bankshares to merge with Cambridge Bancorp in $528M deal - Eastern Bankshares (EBC) announced that its wholly owned subsidiary Eastern Insurance Group entered into a definitive agreement to sell its insurance operations to Arthur J. Gallagher & Co. (AJG) for approximately $510M. Also today, Eastern and Cambridge Bancorp (CATC), the parent company of Cambridge Trust Company, announced they have entered into a definitive merger agreement pursuant to which Cambridge will merge with and into Eastern in an all-stock transaction valued at approximately $528M. Under the terms of the merger agreement, which has been unanimously approved by both boards of directors, each share of Cambridge common stock will be exchanged for 4.956 shares of Eastern common stock. Eastern anticipates issuing approximately 39.4M shares of its common stock in the merger. Based upon Eastern's $13.41 per share closing price on September 18, 2023, the transaction is valued at approximately $528Mand the aggregate consideration represents 114% of Cambridge's tangible book value and a 24% premium to Cambridge's thirty-day volume weighted average price. Upon closing, Denis Sheahan, Chairman, President and CEO of Cambridge, will become the CEO of Eastern and will join Eastern's Board of Directors. Eastern's President Quincy Miller will be promoted to Vice Chair, President, and Chief Operating Officer. Both Mr. Sheahan and Mr. Miller will report directly to Bob Rivers, who will serve as Executive Chair and Chair of the Board of Directors. In addition to Mr. Sheahan, three Cambridge directors are expected to be elected to Eastern's Board of Directors in connection with the closing. Given the distinction of the Cambridge Trust brand in the banks' shared local markets, the combined wealth management and private banking divisions will operate under the Cambridge Trust brand and leadership. Also today, Eastern announced that Eastern Insurance has entered into a definitive agreement to sell its insurance operations to Arthur J. Gallagher & Co., for approximately $510M in cash consideration. On an after-tax basis, the net gain on sale is expected to be approximately $260M. Eastern anticipates that the insurance transaction, which is subject to standard closing conditions, will close in the fourth quarter of 2023. In connection with the sale, current leadership and employees of Eastern Insurance are expected to join Gallagher.

16:16 EDT Sylvamo announces special dividend of 30c per share - The dividends are payable Oct. 17, 2023, to holders of record at the close of business Oct. 3, 2023.

16:16 EDT Sylvamo raises quarterly 20% to 30c per share - The dividends are payable Oct. 17, 2023, to holders of record at the close of business Oct. 3, 2023.

16:10 EDT Eastern Bankshares trading halted, news pending

16:06 EDT Sonder Holdings announces reverse stock split to regain Nasdaq compliance - Sonder Holdings "announced that it will effect a reverse stock split of its common stock at a reverse stock split ratio of 1-for-20, effective as of the close of trading on September 20, 2023, in order to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5450(a)(1). The Company's common stock is expected to begin trading on a reverse-split-adjusted basis on Nasdaq as of the open of trading on September 21, 2023 under the existing ticker symbol 'SOND'."

16:04 EDT Taysha Gene Therapies to discontinue development of TSHA-120 program - Taysha Gene Therapies announced that subsequent to the receipt of Type C meeting feedback from the FDA regarding a registrational path for TSHA-120, the company will discontinue the development of its TSHA-120 program in evaluation for the treatment of giant axonal neuropathy, or GAN. Further, Taysha announced that Astellas Gene Therapies has elected not to exercise its option to obtain an exclusive license to TSHA-120 under the option agreement between Astellas and Taysha. FDA Type C meeting feedback indicated that the FDA continues to recommend a randomized, double-blind, placebo-controlled trial as the optimal path to demonstrate efficacy in TSHA-120. Among other areas of feedback, the FDA also provided a potential path for a single-arm trial with an external control group matched with to-be treated patients by multiple prognostic factors and recommended longer term follow up to account for potential bias.

16:02 EDT Inhibrx announces Chiesi Farmaceutici declined option for rights on INBRX-101 - Inhibrx announced that Chiesi Farmaceutici declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency, or AATD. Inhibrx's delivery of the European Medicines Agency, or EMA, scientific advice to Chiesi triggered a 60-day option period to obtain an exclusive license to develop and commercialize INBRX-101 for the treatment of patients with AATD outside of the United States and Canada. On September 18, 2023, Chiesi notified Inhibrx it was declining this option.

15:35 EDT Pinterest up 4% in late trading as investor day continues - Pinterest shares are up $1.08, or 4%, to $26.48 in afternoon trading as the company's investor day event continues.

15:12 EDT Intel sees gross margin expansion in 2024, not 'hundreds and hundreds' of points - According to a transcript of a Q&A session during the Intel Innovation 2023 event, Intel executives stated: "And so I, you know, year over year we'll see gross margin expansion. It may not be, you know, hundreds and hundreds of basis points next year. It may be more modest for the reasons I talked about from a headwind perspective. But we do expect margin expansion next year."

15:07 EDT Intel sees 'inventory digestion' in upcoming quarters in data center business - According to a transcript of a Q&A session during the Intel Innovation 2023 event, Intel executives stated: "I don't want to give anybody the impression that, you know, this thing, that the business is going to be up this and a lot of that is actually our FPGA business had a huge backlog. And they're at the point now where they've kind of satisfied a lot of that, the pent up demand. And so there was, you know, kind of a natural correction we were going to see in the FPGA business, which we which we have seen. In addition, know we did expect some share loss this half of the year. In fact, we thought we would see share loss in the first half of the year. We actually held share better in the data center business than we thought. But, you know, we do expect to see a little bit of that in the back half of the year. And then lastly, there's there was a lot of inventory the channel in data center and, you know, much like client, by the way, but client kind of recognized it earlier and kind of worked that inventory that through the system. And we're now kind of seeing the recovery from that data center was a little bit more delayed. And so, you know, and we have to see the recovery from that. So that will you know, inventory digestion we're going to see for Q3 for sure and likely for Q4 before we start seeing that turnaround on the, we will see revenue this quarter, but it will be modest."

14:58 EDT American Software sells consulting firm The Proven Method to Marathon TS - American Software announced that they signed an agreement for the sale of their information technology consulting firm, The Proven Method to Marathon TS, Inc., an IT professional services firm. This sale closed on September 18. "American Software divested The Proven Method to focus on their core supply chain planning business allowing Logility, the operating entity of American Software, to continue to expand its AI-first supply chain management platform. Designed for speed and agility, Logility's cloud-based platform provides a unique blend of Generative AI, advanced AI-driven algorithms, machine learning, and predictive analytics to help deliver integrated planning and operations across the end-to-end supply chain," the company stated. "Supply chain planning is entering a significant transformation with advancements in technology, generational shifts of the workforce, and the significant speed of market changes and disruptions. This divestment optimally positions us to concentrate on delivering modern, breakthrough technology to the supply chain industry," added Allan Dow, CEO American Software.

14:49 EDT Bird Global trading resumes

14:30 EDT Bird Global says Skinny Labs deal to be immediately accretive - Bird Global announced it has acquired shared electric bike and scooter operator Skinny Labs, doing business as Spin, from Berlin-based TIER Mobility. The transaction is expected to be immediately accretive to earnings. Spin is now a wholly-owned subsidiary of Bird Rides. The purchase price was $19M, including $10M in upfront cash, $6M in a vendor take back and $3M as a hold back. This transaction was supported by MidCap Financial Investment and MidCap Financial Trust, managed or advised by Apollo Capital Management. For the 12 months ended June 30, Spin delivered approximately $45M in net revenue, bringing the combined net revenue for Bird and Spin to approximately $265M for that period. The transaction is expected to have upwards of $20M in synergies and be immediately accretive to earnings for Bird, due in part to recent operational restructuring. Bird said, "Spin, which is headquartered in San Francisco, has a strong presence in North America including operations in over 50 cities and university campuses with minimal overlap with Bird's existing footprint. The acquisition increases Bird's geographical footprint, solidifying its position as the leading micromobility operator in North America by market share and by number of markets serviced. The company plans to leverage this leadership position to further expand its operations in multiple profitable key cities such as Baltimore, Salt Lake City, and Washington D.C, one of the top micromobility markets for cash flow in North America, as well as major university campuses such as Penn State University and the University of Michigan. Combined with Spin, Bird now operates in 87% of the 50 most populous cities in the United States and Canada2 that have a shared micromobility program."

14:18 EDT Novartis' Sandoz gets FDA approval for intravenous Cyclophosphamide Injection - In a letter to Sandoz's Gregory Seitz, Executive Director, Regulatory Affairs, the FDA stated: "Please refer to your new drug application dated and received August 12, 2022, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Cyclophosphamide Injection for intravenous use. We acknowledge receipt of your major amendment dated June 5, 2023, which extended the goal date by three months. This NDA provides for the use of Cyclophosphamide Injection for the treatment of adult patients with malignant lymphomas: Hodgkin's lymphoma, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling." Reference Link

14:03 EDT Warner Bros. Discovery says sports tier to launch on Max in U.S. on October 5 - Max and Warner Bros. Discovery Sports announced a Bleacher Report Sports Add-On tier is coming to Max starting Thursday, October 5 in the U.S. "This will mark the first time that fans will have access on streaming platforms, in addition to linear, to WBD's portfolio of premium live sports content, including more than 300 live games each year... Following a promotional period through February 29th, during which the B/R Sports Add-On will be available to U.S. subscribers for no additional charge, the offering will be made available in the U.S. as an add-on to all Max entertainment packages -- Max With Ads, Max Ad-Free and Max Ultimate Ad-Free -- for $9.99 per month," the company stated.

13:34 EDT Murphy Canyon Acquisition Corp trading halted, volatility trading pause

13:11 EDT 10x Genomics says UPC grants preliminary injunction against NanoString - 10x Genomics (TXG) announced that the European Unified Patent Court, or "UPC," issued a preliminary injunction against NanoString Technologies (NSTG) for infringing European Patent 4 108 782 B1. "The preliminary injunction, issued by a panel of four judges with both legal and technical expertise, prevents NanoString from selling or providing services using its CosMx Spatial Molecular Imager instruments and CosMx reagents for RNA detection in all 17 countries of the UPC," the company stated. Eric Whitaker, Chief Legal Officer for 10x Genomics, said: "Since the formation of 10x, our unwavering commitment has been to drive innovation to push science forward. We have made massive investments in cutting edge research and development resulting in revolutionary products transforming the world's understanding of health and disease. The entire purpose of patent systems around the world is to protect such innovations and encourage such investments. We will be steadfast in protecting the inventions that scientists have worked so hard to create, as innovation is what fuels and funds the development of future 10x technologies that benefit researchers - and ultimately patients. A patent holder must meet a very high standard to win a preliminary injunction. Two separate courts have now found that NanoString's CosMx products infringe two different 10x patents, and three separate courts have preliminarily found the 10x patents valid in the asserted scope. In total, three courts have analyzed hundreds of pages of arguments made by NanoString and have rejected NanoString's repeated claims that it does not infringe 10x patents, that the patents are invalid or that NanoString's claims to a license have merit. Although we welcome legitimate competition on the merits, competition based on our own innovations must stop."

12:08 EDT Workiva announces enhanced leadership team, including CIO, CAO, CPO - Workiva hosted its annual Analyst & Investor Day in which company management showcased its growth strategy, continued relevance and opportunities in capturing global markets, and commitment to relentless platform and product innovation. The company also announced an enhanced senior leadership team whowill collectively set the pace for scaling Workiva to $1B in annual revenue and beyond. Workiva has enhanced its leadership team Kim Huffman, Chief Information Officer; Junko Swain, Chief Accounting Officer; Nitin Bhat, Chief Product Officer; and Noam Bizman, SVP of North American Sales. "We recently added an infusion of experienced executives to our senior leadership team to provide the depth and resources we need to scale our business and meet our growth objectives," the company said.

12:03 EDT Switchback II trading halted, news pending

12:02 EDT Amazon.com hiring 250,000 full-time, seasonal, part-time employees in U.S. - Amazon announced that it is hiring 250,000 employees throughout the U.S. in full-time, seasonal, and part-time roles across its operations network, and 30,000 of those will be across California. A diverse range of roles-from packing and picking to sorting and shipping-are available to applicants from all backgrounds and experience levels, Amazon said in a statement. "The holiday season is always a special time at Amazon and we're excited to hire 250,000 additional people this year to help serve customers across the country," said John Felton, Amazon's Senior Vice President of Worldwide Operations. Reference Link

12:00 EDT Amprius Technologies falls -10.9% - Amprius Technologies is down -10.9%, or -55c to $4.48.

12:00 EDT Endava rises 8.0% - Endava is up 8.0%, or $4.07 to $55.07.

12:00 EDT NanoString says will 'immediately appeal' preliminary injunction in EU - NanoString Technologies (NSTG) issued comments on today's order from the European Unified Patent Court, or UPC, granting a preliminary injunction effective immediately in 17 Member States of the European Union against NanoString's CosMx Spatial Molecular Imager products for RNA detection in NanoString's ongoing patent dispute with 10x Genomics (TXG) and Harvard, stating in part: "We are disappointed with today's decision by the UPC and will immediately appeal the preliminary injunction in the UPC Court of Appeal in Luxembourg. We are confident in our belief that we do not infringe the asserted patents, and that the patents will ultimately be found to be invalid. We also respectfully believe the court erred by failing to adequately consider evidence demonstrating that the patents asserted by 10x were funded by a grant of over $19 million from the National Institutes of Health that required open and non-exclusive licensing to promote the public interest... We believe that 10x Genomics has resorted to the courts and is misusing non-final court rulings as part of its commercial strategy to eliminate competition in the spatial transcriptomics market to the detriment of the public good. NanoString provides the scientific community with highly differentiated spatial biology tools with capabilities for both spatial transcriptomics and spatial proteomics that exceed those of any other spatial analysis systems... NanoString is committed to defending a competitive, innovative marketplace. We will immediately appeal the decision to the UPC Court of Appeal in Luxembourg. We look forward to presenting multiple arguments to invalidate the asserted patents and demonstrate our non-infringement of these patents at the full UPC hearings on the merits of our case. We do not yet have a date for those hearings."

11:57 EDT NanoString says will 'immediately appeal' preliminary injunction in EU - NanoString Technologies issued comments on today's order from the European Unified Patent Court, or UPC, granting a preliminary injunction effective immediately in 17 Member States of the European Union against NanoString's CosMx Spatial Molecular Imager products for RNA detection in NanoString's ongoing patent dispute with 10x Genomics and Harvard, stating in part: "We are disappointed with today's decision by the UPC and will immediately appeal the preliminary injunction in the UPC Court of Appeal in Luxembourg. We are confident in our belief that we do not infringe the asserted patents, and that the patents will ultimately be found to be invalid. We also respectfully believe the court erred by failing to adequately consider evidence demonstrating that the patents asserted by 10x were funded by a grant of over $19 million from the National Institutes of Health that required open and non-exclusive licensing to promote the public interest... We believe that 10x Genomics has resorted to the courts and is misusing non-final court rulings as part of its commercial strategy to eliminate competition in the spatial transcriptomics market to the detriment of the public good. NanoString provides the scientific community with highly differentiated spatial biology tools with capabilities for both spatial transcriptomics and spatial proteomics that exceed those of any other spatial analysis systems... NanoString is committed to defending a competitive, innovative marketplace. We will immediately appeal the decision to the UPC Court of Appeal in Luxembourg. We look forward to presenting multiple arguments to invalidate the asserted patents and demonstrate our non-infringement of these patents at the full UPC hearings on the merits of our case. We do not yet have a date for those hearings."

10:50 EDT Exxon Mobil awarded four carbon storage testing licenses by U.K.'s NSTA - Exxon Mobil (XOM) announced that its Low Carbon Solutions business was awarded four licenses to test for potential locations to store captured CO2 emissions deep underneath the U.K. North Sea. The company will partner with Shell (SHEL) on three of the licenses, and Neptune Energy on the fourth. The licenses were awarded by U.K. regulator the North Sea Transition Authority, or NSTA. The licenses are off the east coast of England, in waters where Exxon Mobil has developed oil and gas resources for decades. If assessments prove successful, the company will apply to the U.K. government for permission to develop the carbon storage projects, which would support the U.K.'s ambition to store more than 50 million metric tons of carbon annually by 2050. The potential storage areas are a mix of depleted oil and gas reservoirs and saline aquifers. Reference Link

10:32 EDT Abbott's TactiFlex Ablation Catheter used to treat AFib in Alberta - Abbott announced that the company's TactiFlex Ablation Catheter, Sensor Enabled has been used for the first time in Canada at the Foothills Medical Centre in Calgary, Alberta, to treat atrial fibrillation.

10:28 EDT DatChat announces 1:10 reverse stock split, effective September 20 - DatChat announced that it will effect a 1-for-10 reverse split of its issued and outstanding and authorized common stock. Commencing with the opening of trading on The Nasdaq Capital Market on September 20, the company's common stock will trade on a post-split basis under the same trading symbol, "DATS". The reverse stock split is primarily intended to bring the company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing; however, no assurance can be given that such reverse stock split will enable the company to regain compliance with the Nasdaq minimum bid price requirement. The company corrected a prior statement that said the effective date was September 19.

10:17 EDT LyondellBasell: Q3 profitability playing out better than expected - Comments taken from the J.P. Morgan 14th Annual U.S. All Stars Conference.

10:07 EDT Enphase Energy rallies after director buys over $4M of shares - Enphase Energy director Thurman Rodgers disclosed last night the purchase of 32,600 shares at an average price of $122.76, for a value of over $4M. Rodgers now owns 93,400 indirect and 1,526 direct shares of Enphase. Shares of Enphase Energy are up 4% to $121.40 in morning trading.

10:04 EDT Weave delivers over 1.8B unique customer interactions - Weave announced that its 27,000+ customers used Weave's platform to interact with their patients more than 1.8 billion times in the last twelve months. The company said, "This remarkable milestone demonstrates the ever-growing need for modern and convenient communication, engagement and payment tools."

10:01 EDT Mullen Automotive receives IRS approval for federal EV tax credit - Mullen Automotive announces the Company has received approval from the IRS, receiving its "qualified manufacturer" designation enabling qualification for commercial EV federal tax credits of up to $7,500 per qualified vehicle with gross vehicle weight ratings of under 14,000 pounds. The company is pleased to announce that both the Mullen ONE, a Class 1 EV Cargo Van, and the Mullen THREE, a Class 3 EV Cab Chassis Truck, are now approved for EV federal tax credits of up to $7,500 per qualified vehicle. Additionally, according to the relevant IRS regulation, vehicles with gross vehicle weight ratings of over 14,000 pounds can qualify for $40,000 federal EV tax credits. Mullen received this designation on Sept. 14, 2023, as a "Qualified Manufacturer" as defined in Section 30D(d)(3) of the Internal Revenue Code.

10:00 EDT Nio falls -8.7% - Nio is down -8.7%, or -90c to $9.41.

10:00 EDT Redwire rises 5.7% - Redwire is up 5.7%, or 19c to $3.54.

10:00 EDT Cooper-Standard rises 8.2% - Cooper-Standard is up 8.2%, or $1.28 to $16.93.

09:47 EDT CNFinance falls -5.9% - CNFinance is down -5.9%, or -20c to $3.18.

09:47 EDT TortoiseEcofin Acquisition Corp. III rises 4.8% - TortoiseEcofin Acquisition Corp. III is up 4.8%, or 51c to $10.97.

09:47 EDT Kaleyra rises 5.1% - Kaleyra is up 5.1%, or 35c to $7.15.

09:40 EDT CF Acquisition Corp VIII trading resumes

09:37 EDT Dish gets U.S. DOJ support to extend deadline on T-Mobile airwaves deal - In a filing with the U.S. District Court for the District of Columbia made by the Justice Department related to Deutsche Telekom (DTEGY), T-Mobile (TMUS), Sprint, and Dish's (DISH) agreement to a final judgement to remedy "the loss of competition" from T-Mobile's acquisition of Sprint, the United States "respectfully requests that if the Court grants DISH's request to modify the Final Judgment in this matter, that the Court give DISH until April 1, 2024, to exercise the option." The filing added: "To facilitate the orderly divestiture of the 800 MHz spectrum, DISH has agreed to (i) waive any right to seek additional extensions so that the spectrum does not lie fallow for an unknown period, see DISH Reply at 5, and (ii) it has represented to the United States that it will waive its right to enforce the non-solicitation clause in the License Purchase Agreement so that T-Mobile can concurrently conduct the auction process."

09:35 EDT Digital Transformation Opportunites Corp trading halted, volatility trading pause

09:27 EDT VirnetX partners with Zeleration Technology for online privacy - VirnetX has signed a non-exclusive agreement with Zeleration Technology, creating a new partnership for the sale, integration, and support of VirnetX's Cybersecurity and Secure Communication Solutions, within Zeleration's ecosystem, first catering to businesses in consulting, finance, accounting, and law.

09:24 EDT Immix Biopharma's Nexcella completes 2nd NXC-201 engineering batch - Immix Biopharma announced the successful completion of its 2nd CAR-T NXC-201 engineering batch at its U.S. manufacturing site. This represents an important step forward in the planned U.S. expansion of the Company's ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T cell therapy NXC-201. "The completion of our 2nd U.S. engineering batch is a key step towards expanding our NXC-201 clinical trial to the United States," said Ilya Rachman, M.D. PhD Chief Executive Officer of Immix Biopharma. "Not only is NXC-201 the first CAR-T in AL amyloidosis, in addition we believe NXC-201's observed zero neurotoxicity and favorable tolerability profile across 58 patients to-date could enable expansion into earlier lines of therapy and out-patient NXC-201 dosing."

09:21 EDT Strong Studios, Convergent Media, ForLan Films partner for drama series - Strong Global Entertainment announced that its subsidiary Strong Studios will partner with Convergent Media, U.K.'s ForLan Films and M-Net/Multichoice Africa to produce the new crime drama series, Endangered. The project is based on one of a series of bestselling novels from the popular South African crime writer, Rudie Van Rensburg.

09:19 EDT Hershey appionts Deepak Bhatia as Chief Technology Officer - Hershey appointed Deepak Bhatia as its first Chief Technology Officer and newest member of its Executive Committee. He was formerly the VP of Supply Chain Optimization Technologies at Amazon. Prior to Amazon, Bhatia spent 11 years at Applied Materials. His first day at Hershey will be on October 23.

09:17 EDT Anika Therapeutics announces full market release of RevoMotion RSA - Anika Therapeutics announced the full market release of their RevoMotion Reverse Shoulder Arthroplasty System, RSA, at the 2023 Orthopaedic Summit, OSET, Annual Meeting on September 20-23 in Boston, MA. "We're excited to participate in this year's OSET Annual Meeting, where we are showcasing our breakthrough new products focused on early intervention orthopedics, including the launch of our RevoMotion Reverse Shoulder Arthroplasty System, designed specifically to address clinical needs through a truly bone preserving design with simple and efficient instrumentation," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "We are also thrilled to preview at OSET our recently cleared Integrity regenerative HA-based rotator cuff patch system, which is uniquely strong, versatile, and easy-to-use. Integrity has an innovative delivery and fixation system and has greater regenerative capacity compared to first generation collagen patches. Anika's cutting-edge shoulder portfolio, which also includes our recently launched X-Twist suture anchors, Tactoset HA-enhanced injectable bone substitute cleared for hardware augmentation, and OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty, is further reinforced by the full market launch of RevoMotion.."

09:15 EDT Stran & Company appoints David Leuci as CIO - Stran & Company announced that it has appointed David Leuci, an experienced information technology executive, as Chief Information Officer, CIO. Leuci will play a key role in enhancing Stran's overall technology strategy, execution and leadership. Most recently, Leuci served as Chief Digital Information Officer at The Energy Federation.

09:14 EDT Cepton names Mitch Hourtienne Chief Commercial Officer - Cepton announced the appointment of Mitch Hourtienne to Chief Commercial Officer, overseeing the Company's business growth and market success. In the newly created role, Mr. Hourtienne will continue to lead Cepton's business development, product management and marketing teams to solidify the Company's leadership in automotive and smart infrastructure markets and strengthen strategic partnerships with world-class industry leaders.

09:13 EDT DatChat Inc trading halted, news pending

09:11 EDT Taboola teams with Gannett in five-year content recommendation partnership - Taboola (TBLA) announced a renewed partnership with Gannett (GCI), which reaches 133M monthly unique visitors across the USA TODAY Network and publishes USA TODAY along with over 200 local media outlets across 43 U.S. states. In this new deal, Gannett will test additional Taboola offerings including Homepage For You, its publisher platform offering that adds Artificial Intelligence to power editorial recommendations on publisher homepages. Homepage For You is part of Taboola Newsroom, a real-time analytics platform that provides unique insights, sourced from Taboola's dataset of nearly 600 million daily active users, which inform how to create more engaging content and discover new coverage areas that drive loyal readership. Gannett will also explore the option to adopt Taboola Turnkey to support its consumer product review site, Reviewed, part of the USA TODAY Network.

09:10 EDT Edible Garden signs agreement to distribute produce, products to Woodman's - Edible Garden announced it had signed an agreement to distribute Edible Garden's produce and products to all nineteen Woodman's Markets locations across Wisconsin and Illinois. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are excited to announce the availability of Edible Garden's products at Woodman's Markets, which we believe reflects our growing reputation as a trusted, dependable, supplier and focus on sustainably grown produce. Importantly, Woodman's Markets plans to feature our patented, self-watering display chain wide. This also marks a significant expansion of our distribution in the Midwest and allows us to leverage our new Edible Garden Heartland facility. Woodman's large retail locations average 230,000 square feet, are open 24 hours a day, 7 days a week, and carry a wide variety of products, resulting in high traffic volume-making them an ideal partner for Edible Garden."

09:08 EDT Hancock Whitney sees higher loan loss provision, net charge offs in Q3 - In a regulatory filing yesterday, Hancock Whitney disclosed that it seen a higher provision for loan losses and net charge offs, driven by $30M charge-off on a 13.7% participation in a syndicated credit. The company also states that it is "not experiencing broad signs of weakness among any industry, collateral type, or geography, and excluding the "idiosyncratic" charge-off, Q3 net charge offs are expected to be within normal range. Reference Link

09:08 EDT Conduent's BenefitWallet HSA portfolio moving to HealthEquity - Conduent Incorporated (CNDT) and HealthEquity (HQY) entered into a definitive agreement to transfer BenefitWallet's Health Savings Account portfolio to HealthEquity. The agreement contemplates a purchase price of approximately $425 million for the transition of all BenefitWallet HSA accounts, including approximately 665,000 customer accounts and their approximately $2.7 billion of HSA assets to HealthEquity.The transfer of the BenefitWallet HSA assets to HealthEquity is expected to close in multiple tranches during the first half of 2024 and is subject to regulatory approval and the satisfaction of certain other customary closing conditions. With respect to use of proceeds, Conduent intends to continue with a balanced approach to capital allocation including maintaining modest levels of net leverage.

09:07 EDT Pulmatrix's IND application for PUR3100 to treat acute migraine accepted by FDA - Pulmatrix announced the FDA has accepted the PUR3100 investigational new drug application and the company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 in the Acute Treatment of Migraine. The PUR3100 formulation uses Pulmatrix's novel, proprietary dry powder delivery technology, iSPERSE to deliver DHE via oral inhalation using a dry powder inhaler.

09:05 EDT Intapp selected by Warner Norcross + Judd to modernize risk, compliance - Intapp announced that corporate law firm Warner Norcross + Judd LLP has selected Intapp Risk & Compliance, delivered in the Microsoft Azure Cloud, as its risk management and compliance solution. Intapp Risk & Compliance cloud solutions help professionals quickly and thoroughly evaluate new business, onboard clients, and monitor relationships for compliance throughout the client lifecycle. As a part of this suite, Warner will use: Intapp Conflicts and Intapp Terms. "When it comes to risk and compliance, it's essential that we provide our attorneys and staff with the resources to make smart and efficient decisions on our client intake. Currently, this requires a lot of manual and time-consuming work for our professionals," said Paul Boehms, Executive Director at Warner. "Moving to Intapp will allow us to onboard clients and accept new deals faster and without worry by simplifying reporting, enhancing search, and reducing the number of irrelevant conflicts that require manual review."

09:05 EDT Ally Financial launches proprietary, enterprise AI platform - Ally Financial announced the launch of Ally.ai, a proprietary, cloud-based artificial intelligence platform that has the functionality of traditional and generative AI tools, including foundational models, along with the specialized human touch and data security protections essential for a financial services company. Ally's roadmap for AI is focused on strategic problem solving and future scalability with significant emphasis on human training, feedback and oversight. The Ally.ai platform allows Ally to integrate any type of AI capability, including generative AI and large language models, into business operations at an enterprise scale.

09:04 EDT CPS Technologies receives SBIR award - CPS Technologies announced that it has received a phase I SBIR award, valued at approximately $200,000, from the U.S. Department of Energy, its first such grant from this agency. The study, entitled "Modular Radiation Shielding for Transportation and Use of Microreactors," will be led by Matthew Karnick, a materials scientist at the Company. "I am very pleased to announce this new phase I SBIR," said Brian Mackey, President & CEO of CPS. "It is our fifth SBIR/STTR award since such work became a priority for CPS a little over a year ago. More importantly, it represents our first award from the U.S. Department of Energy, which demonstrates the relevance of our capabilities to the diverse needs of various federal agencies. I'm confident that CPS' renewed focus on R&D will have a positive impact on our future growth. In addition, I'm very excited to recognize Matthew Karnick as the third CPS materials scientist to receive an award of this nature."

09:03 EDT Creative Realities expands partnership with Target Center - Creative Realities announced its partnership with Target Center to transform the fan experience with advanced digital signage technology. Through the partnership, Creative Realities will upgrade the arena's full IPTV and digital signage platforms, including software, displays and video walls, as well as deliver content creation design and optimization strategy. After evaluating many integration partners and software platforms, Target Center - managed by ASM Global - selected Creative Realities due to its consultative approach to guiding technology selection and strategy, as well as its deep experience with top sports and entertainment venues. With planning currently in progress, Creative Realities and Target Center will define the complete rollout schedule during the 2023-2024 NBA season, coinciding this implementation with other planned venue upgrades.

09:02 EDT T2 Biosystems receives FDA 510(k) clearance for T2Biothreat Panel - T2 Biosystems received 510(k) clearance from the U.S. Food and Drug Administration for the T2Biothreat Panel. The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market. The T2Biothreat Panel is a direct-from-blood molecular diagnostic test that runs on the FDA-cleared T2Dx Instrument and simultaneously detects six biothreat pathogens, including the organisms that cause anthrax, tularemia, glanders, melioidosis, plague, and typhus. These pathogens have been identified as threats by the U.S. Centers for Disease Control and Prevention and identified as material biological threats under section 319-2(c)(2)(A)(ii) of the Public Health Service Act.

09:02 EDT Myriad Genetics, Illumina achieve milestones in strategic partnership - Myriad Genetics (MYGN) announced two key milestones in its strategic partnership with Illumina Inc. (ILMN) to advance and support clinical research for gene-based, targeted therapies. Under the strategic partnership, Myriad and Illumina are working together to advance comprehensive genomic profiling plus homologous recombination deficiency testing using the globally distributed Illumina TruSight Oncology 500 assay, which enables comprehensive genomic profiling by analyzing 523 genes across DNA and RNA variants. The first milestone achieved qualifies Myriad to conduct prospective clinical trial testing with an investigational use only test based off of Illumina's in-development IVD solution, TruSight Oncology Comprehensive test. This positions Myriad to partner with leading pharmaceutical companies and academic institutions to further development of companion diagnostics. The second milestone involves Myriad's initiation of its first reproducibility test project to support future regulatory filings for TSO Comp. Myriad now provides support in Illumina's partnerships with pharmaceutical companies to develop companion diagnostics on TSO Comp.

08:46 EDT Eltek receives $2.9M purchase order from existing customer - Eltek has received a purchase order in the amount of $2.9M from an existing customer. The order will be supplied by Eltek over a period of 16 months commencing in February 2024.

08:45 EDT BK Technologies president Tim Vitou to retire - BK Technologies Corporation announced that President Tim Vitou will retire effective October 12, 2023. John Suzuki, BK's CEO will assume the responsibilities of President.

08:41 EDT Rigetti awarded five-year contract with AFRL for quantum foundry services - Rigetti Computing announced that it was awarded a five-year Indefinite Delivery Indefinite Quantity, IDIQ, contract with the Air Force Research Lab, AFRL, Information Directorate to supply its researchers with quantum foundry services. This contract allows AFRL to leverage Rigetti's fabrication and manufacturing capabilities to build customized quantum systems. Within the scope of the contract, Rigetti will be able to provide quantum integrated circuits, quantum-limited amplifiers, cryogenic microwave components, and 9Q QPUs. "We are extremely privileged that AFRL's world-class team of researchers have chosen to use Rigetti's fabrication facilities and expertise to conduct its critical, fundamental research on how to build the next generation of quantum networks," said Dr. Subodh Kulkarni, Rigetti Chief Executive Officer. "Being granted an IDIQ contract with such an esteemed institution reinforces our existing partnership, and demonstrates the value of our fabrication capabilities."

08:39 EDT Sportsman's Warehouse appoints Sansom to its board of directors - Sportsman's Warehouse announced that Steven Sansom has been appointed to the Company's Board of Directors, effective September 15, 2023. He will serve as a member of the Board's Compensation Committee. Sansom is a corporate executive with over 30 years of experience in high-growth businesses. He has served as founder and chairman of Steel Grove Capital Advisors and Steel Grove Family Office in Memphis, Tennessee since September 2001.

08:38 EDT Mondee appoints Clarke to board of directors - Mondee announced the appointment of Jeff Clarke to its Board of Directors. The independent appointment is effective September 14, 2023, following unanimous election by the Company's Board of Directors. Currently, Clarke is serving as Interim CEO at Doxim, a customer communications management and engagement technology provider.

08:37 EDT Bridgeline Digital announces top financial institution expanded its license - Bridgeline Digital announced that a top financial institution has expanded their license contract to include the Bridgeline Accessibility Packaged Solution powered by accessiBe. With this additional 24-month license engagement, Bridgeline has expanded the credit union's lifetime value, exceeding $1.1 million dollars over the course of this long-term partnership. The financial institution has leveraged Bridgeline's Unbound platform to power their site, what they refer to as their "top performing branch." They have selected Bridgeline's Accessibility Packaged Solution powered by accessiBe after recognizing the need to ensure its website is accessible to all and compliant with the Americans with Disabilities Act. With this new agreement, the institution will automate their compliance processes to not only appeal to a broader audience for a more inclusive experience, but to also minimize risks of litigation.

08:35 EDT ReShape Lifesciences strengthens patent portfolio related to Obalon system - ReShape Lifesciences announced that the company has significantly strengthened the patent portfolio related to its Obalon Balloon System. Specifically, the U.S. Patent and Trademark Office has granted one patent and provided the company with a Notice of Allowance for two additional patents, providing foundational protection of the system. Granted U.S. Patent No. 11,737,899, entitled "Intragastric Device," covers claims for an intragastric balloon system with a needle assembly comprising a catheter needle sleeve and needle for inflation of the balloon system, among other claims. Notice of Allowance for patent application 16/993,110, entitled, "Pressure Control System For Intragastric Device." If issued, the patent would include claims directed to systems and methods for inflating an intragastric device. Notice of Allowance for patent application 17/581,792, entitled, "Intragastric Device."

08:34 EDT KULR Technology pays down outstanding note - KULR Technology Group announced the Company has paid down more than 20% of its outstanding note to YA II PN, LTD.

08:33 EDT Resideo reaches agreement to sell Genesis cable business to Southwire for $87.5M - Resideo announced a definitive agreement for the sale to Southwire Company of its Genesis Cable business, a low-voltage wire and cable manufacturer based in Pleasant Prairie, WI. The transaction is valued at approximately $87.5M, subject to customary closing conditions and is anticipated to close in the next 30 days. Genesis is a U.S. low-voltage cable manufacturer, providing critical connection for a wide range of residential and commercial applications with 187 employees and manufacturing in Pleasant Prairie, WI. The transaction is expected to have minimal impact on Resideo's Q4 operating income and is expected to be immediately accretive to Products & Solutions gross and operating margin. Resideo expects to use the net proceeds from the transaction for ongoing organic and inorganic investment and to support capital return to shareholders through the recently announced share repurchase program.

08:32 EDT Maris-Tech receives new order for $234,000 from governmental agency - Maris-Tech announced that it has received a new order from an Israeli government defense agency, for a customized solution. The Company will develop a unique system for sophisticated intelligence-gathering applications based on Maris-Tech's powerful solutions, incorporating advanced video streaming and recording capabilities. Maris-Tech anticipates receiving additional follow-up orders for system production and delivery. "This order to develop a product featuring our cutting-edge intelligence gathering capabilities based on our innovative technology underscores Maris-Tech's continued success meeting the evolving needs for homeland security and defense platforms with high-performance solutions in flexible configurations," said Israel Bar, Chief Executive Officer of Maris-Tech.

08:29 EDT LCCMR recommends 374Water project for trust fund allocation - A project involving 374Water recently received approval for funding from the Legislative-Citizen Commission on Minnesota Resources. The team's study, "Breaking the PFAS Cycle with a Full-Scale Demonstration" was selected for inclusion in the LCCMR's annual recommendations to the Minnesota Legislature on how to allocate proceeds from the state's Environment and Natural Resources Trust Fund. 374Water is part of a project team comprised of Barr Engineering Co. in Minneapolis, MN; University of St. Thomas in St. Paul, MN; Minnesota Technical Assistance Program at the University of Minnesota in Minneapolis, MN; and City of St. Cloud, MN. The project will utilize 374Water's commercial AirSCWO 6 supercritical water oxidation system to eliminate PFAS in biosolids and water treatment residuals. The system eliminates harmful chemicals, including PFAS and other biohazards found in a variety of wastes, and recovers energy, minerals, and clean water, which could aid municipalities and citizens throughout Minnesota impacted by this new generation of emerging contaminants. The initiative will enable a comprehensive evaluation of PFAS destruction efficiency and explore options for either disposing of or reusing the treated water and solids. The goal of this public-private partnership is to evaluate the ability of SCWO to destroy PFAS in a range of wastes while remaining energy neutral. The project is one of 101 included in the LCCMR's recommendation following its 2024 Request for Proposals, in which they received over 200 proposals requesting a total of approximately $174 million. From this reduced pool, 101 proposals received a recommendation to the Legislature for some portion of the $79,644,000 available. The LCCMR will meet on November 16, 2023 to finalize these recommendations.

08:25 EDT AYRO Vanish completes CARB testing certification - AYRO announced it has passed California Air Resources Board confirmatory testing for the AYRO Vanish. This comes on the heels of the Company's recent announcement that the Vanish successfully met all applicable homologation requirements for both the United States and Canada, by demonstrating compliance with Federal Motor Vehicle Safety Standards, Canada Motor Vehicle Safety Standards and SAE J2358.

08:23 EDT Ormat Technologies secures contract with Mercury NZ - Ormat Technologies announced that the Company has signed new contracts with Mercury NZ Limited for the supply and Engineering, Procurement and Construction of a new 56 MW geothermal power plant at Ngatamariki, New Zealand. Under the agreement with Mercury, the project will be an expansion of the existing 96 MW Ngatamariki geothermal power plant in operation, which was also built by Ormat in 2012. The new power plant will be built on the same platform as the existing power plant and once in operation with the new Ormat Energy Converter it will have a total output of over 150 MW. This development, once complete, will make the Ngatamariki facility the largest pure binary power plant in New Zealand and one of the top-5 largest globally. Upon full operation of the Ngatamariki plant, Ormat's advanced geothermal equipment will take the lead in powering nearly 45% of New Zealand's geothermal energy market. Notably, when combined with Ormat's existing geothermal power plants in the country, the Ngatamariki facilities will play a pivotal role in substantially reducing CO2 emissions throughout the region. This will be achieved through the consistent delivery of clean, reliable, and sustainable electricity to the national grid.

08:23 EDT BioAffinity acquires laboratory assets of Precision Pathology Services for $3.5M - bioAffinity Technologies announced the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists, or CAP, and certified under the Clinical Laboratory Improvement Amendments, or CLIA, of 1988. The laboratory assets are being acquired by a new wholly owned subsidiary of bioAffinity Technologies, Precision Pathology Laboratory Services. Precision Pathology provides pathology services to physicians practicing in a variety of outpatient settings and has offered bioAffinity Technologies' CyPath Lung as a laboratory developed test for the detection of early-stage lung cancer. This transaction gives bioAffinity the opportunity to build a commercial laboratory with scale with the goals of accelerating the market uptake and success of CyPath Lung, supporting the test's upcoming 1,800-patient FDA pivotal trial, and pursuing the development and commercialization of additional tests. Precision Pathology was acquired for $3.5M including $2.5M in cash and $1M in bioAffinity common stock.

08:22 EDT SHF Holdings launches line of credit products for cannabis businesses - SHF Holdings, Inc., d/b/a/ Safe Harbor Financial announced the launch of its new portfolio of line of credit products available to cannabis businesses nationwide. The Company's new line of credit offering expands its growing suite of deposit and credit tools to serve a greater number of cannabis enterprises, including those which have previously faced difficulty obtaining debt financing at reasonable terms. Under these new and expanded programs, Safe Harbor, operating jointly with its financial institution partners, will offer credit facilities ranging from $25,000 to $1 million at market-leading, normalized rates. In many cases, these lines of credit can be obtained without hard collateral.

08:21 EDT Qorvo announces smallest low voltage transmit module for cellular IoT - Qorvo announced the latest in its growing portfolio of cellular IoT transmit modules. Qorvo's new multi-band multi-mode RF front end module is optimized for NB-IoT1/2 and LTE Cat-M1/2 3GPP standards. Its compact 3 mm x 3 mm size, low 2.5V operation and multi-band support make it ideal for low-voltage applications such as smart meters, asset tracking and monitoring, wearables and smart infrastructure. The QM55011 delivers expanded NB-IoT and LTE-M operation down to 2.5V, enabling a broader range of battery options and eliminating the size and cost associated with boost converters. Its low power consumption extends battery life for applications where chargers and main power are unavailable. The device is capable of lower voltage operation under certain NB-IoT/LTE-M uses cases. It is also capable of supporting other air standards such as non-terrestrial network and Wireless Smart Utility Network.

08:20 EDT Certara announces 300th regulatory submission milestone - Certara announced it has successfully supported 300 completed submissions to regulatory agencies worldwide. Submissions include those to initiate clinical trials, such as Investigational New Drug or Clinical Trial Application and marketing applications, such as New Drug Applications, Marketing Authorization Applications, Supplemental New Drug Applications, Biologics License Applications, EU Type II variations, and New Drug Submissions. "As the global regulatory drug development environment changes at an ever-increasing pace, Certara has combined regulatory writing expertise with technology platforms that streamline a complex process," said Demetrius Carter, Sr. Vice President, Regulatory Sciences & Medical Affairs at Certara. "The impact for our clients has been the completion of high-quality submissions on time, resulting in faster approvals of life changing therapeutics for patients," said Patrick Smith, President, Certara Drug Development Solutions.

08:18 EDT Dragonfly Energy manufactures lithium battery using recycled battery materials - Dragonfly Energy (DFLI) in collaboration with Aqua Metals (AQMS) has successfully used high-purity lithium hydroxide recovered by Aqua Metals from recycled lithium-ion batteries to manufacture a lithium-based battery cell using Dragonfly Energy's patented dry battery electrode coating technology. The successful recovery of battery-grade lithium hydroxide and cycle testing of a sustainably manufactured lithium battery cell is a significant advancement for sustainable lithium-ion battery production for the companies. The process demonstrates a potential path towards a more circular and sustainable lithium battery manufacturing industry that addresses the finite and costly nature of battery materials. "The use of recycled lithium addresses two major initiatives for Dragonfly Energy; it helps close the loop by filling in that all-important recycling component, and it provides a ready and sustainable supply of lithium for use in upcoming cell production," said Dr. Denis Phares, Chief Executive Officer of Dragonfly Energy. "Dragonfly Energy is committed to securing a robust supply chain that is compliant with the 2022 Inflation Reduction Act - relating to both mineral processing and battery recycling goals - to support our growth and our future expansion efforts while practicing material circularity and sustainability."

08:17 EDT Zscaler partners with Imprivata, CrowdStrike to announce security solution - Zscaler (ZS) announced that it has teamed up with CrowdStrike (CRWD) and Imprivata to deliver a zero trust cybersecurity solution from device to cloud that's custom-made for medical institutions. The new Zscaler integration with the Imprivata Digital Identity Platform will provide visibility, threat protection and traceability for end-to-end, multi-user, shared device access control that are required for organizations to meet regulatory requirements, including HIPAA and HITECH. Through the new Zscaler integration with Imprivata, Zscaler is able to take Imprivata context and leverage the existing integration with CrowdStrike Falcon Zero Trust Assessment score to control access to applications with adaptive, risk-based policies. "Cyberattacks on healthcare organizations are at an all-time high, and protecting patient data is critical to maintaining trust," said Dhawal Sharma, Senior Vice President and General Manager at Zscaler. "Zscaler's integrations with Imprivata, in addition to CrowdStrike, provide much needed help to healthcare organizations in their journey to a zero trust architecture. We're aiding workers and technicians with least privileged access to the healthcare information they need to provide care and maintain the privacy and security of patient data."

08:14 EDT IntelGenx provides regulatory update for Buprenorphine Buccal Film - IntelGenx provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application, ANDA, has been filed with the U.S. Food and Drug Administration by its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed. As previously announced, Xiromed received a Complete Response Letter from the FDA in April 2023. In response to the CRL, Xiromed submitted to the FDA an Amendment to the ANDA, requesting priority review. In an Amendment Acknowledgement received from the FDA by Xiromed, the FDA granted priority review with a Generic Drug User Fee Act goal date for review of the Amendment of March 8, 2024, unless the Agency determines that an inspection is required. Alternatively, if the FDA determines that an inspection is required, the GDUFA goal date is July 8, 2024. "We are pleased with our partner Xiromed's prompt and fulsome response to the CRL, and are looking forward to the Agency's decision," commented Dwight Gorham, IntelGenx's CEO. "Given the recent pre-approval inspection in March 2023 and subsequent approval of our Rizatriptan oral film, we are optimistic that the FDA will decide to review this Amendment without the need for an additional inspection of our facility."

08:13 EDT Airbnb expands Payoneer deal as a preferred global payment provider - Payoneer (PAYO) has extended and expanded its strategic partnership with Airbnb (ABNB). Payoneer is a preferred payment provider for Airbnb across multiple countries, enabling Hosts to get paid quickly and locally. Payoneer's platform connects businesses around the world through a scaled infrastructure and a global, resilient network of bank partners. This not only allows Airbnb Hosts in such locations to get paid locally but also to access and spend funds in a variety of ways, among other benefits. Payoneer offers a range of financial services including global payouts in over 190 countries and territories and access to a Payoneer Account to view and manage transactions, including payments, point-of-sale purchases, and withdrawals. This includes loading funds received directly onto their Payoneer Commercial Mastercard, a corporate debit card that supports cash flow management, expense tracking, offers rewards, and more. "As payment provider for Airbnb, our decade-long collaboration highlights the value of Payoneer's unparalleled global reach and our ability to connect people at scale through one of the world's largest and fastest-growing travel marketplaces," said Ya Wen, SVP of Americas at Payoneer. "Payoneer has been a flexible and responsive provider supporting us with a resilient platform, expansive infrastructure, and extensive capabilities in emerging markets where we see high-growth opportunities," said Sunny Walia, Head of Payments Partnerships and Economics Airbnb.

08:13 EDT Marathon Petroleum joins strategic investor group for Flyscan Systems - Marathon Petroleum (MPC) is joining strategic investors Hatch, Enbridge (ENB) and Business Development Bank of Canada's - BDC - Cleantech Practice to support Flyscan Systems' continued advancement and growth. The funding will enable Flyscan to accelerate commercialization and scale-up of its operations as it continues to enter into commercial agreements with multiple energy companies in North America. Flyscan Systems is a spin-off from Canada's National Optics Institute founded in 2015. Its mission is to help energy companies and all operators of long linear critical infrastructure to better protect their assets, the public and the environment with a positive financial return.

08:11 EDT Clarus confirms receipt of indication of interest on Precision Sport segment - Clarus Corporation confirmed the receipt of a non-binding indication of interest from Warren Kanders to acquire the Company's Precision Sport segment, which is comprised of the Company's Sierra Bullets and Barnes Bullets - Mona, LLC subsidiaries, through an affiliated entity, for approximately $160M on a cash-free, debt-free basis, the terms of which are more fully set forth in the complete text of the Buyer's Proposal, included as Exhibit 1 to Mr. Kanders' statement of beneficial ownership on Schedule 13D/A as publicly filed on September 18, 2023 with the U.S. Securities and Exchange Commission. Mr. Kanders is the Company's Executive Chairman of the Board of Directors. In response to the Buyer's Proposal, the Board formed a special committee of the Board comprised of independent directors to review and evaluate the Buyer's Proposal and any alternative proposals that may be available to the Company, including the possibility of rejecting the Buyer's Proposal and/or any alternative proposals. The Special Committee has been empowered, among other things, to retain financial advisors and counsel to assist it in its directive from the Board. Separately, Keith Enlow, President of the Company's Precision Sport segment, has advised the Company that he will resign his position effective September 29, 2023 in order to pursue other opportunities. Michael J. Yates, the Company's CFO will serve as interim President of the Company's Precision Sport segment until a successor is hired and formally appointed.

08:10 EDT DermTech, Highmark in pact for the foundational assay for DMT - DermTech announced agreements with Highmark. The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test, DMT .Highmark and its Blue-branded affiliates provide health insurance to approximately 7M members in Pennsylvania, West Virginia, Delaware and New York. The Pigmented Lesion Assay or PLA, the foundational assay of the DMT, is an innovative, non-invasive way to rule out melanoma with a 99 percent negative predictive value. NPV. "We are pleased to expand our connection with one of the largest Blues plans in the U.S. and further reduce barriers to access with our test now available as an in-network benefit," said Chris Murphy, senior director of payer access, DermTech. "The DMT test results provide clinicians with objective and actionable genomic data for a suspicious lesion, improve patient care and reduce healthcare costs. After reviewing our portfolio of clinical and health economic data, payers are recognizing the value of our test and resulting benefits to their membership, network providers and health plans." DermTech's total covered lives in the U.S. are approximately 133M, which includes 68M for Medicare/Medicare Advantage and 65M for commercial and governmental payers.

08:09 EDT Replimune Group announces appointment of Hill as CFO - Replimune (REPL) announced the appointment of Emily Hill as Chief Financial Officer. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics (PTCT) and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical companies.

08:07 EDT Sutro Biopharma appoints Gerber as Chief Scientific Officer - Sutro Biopharma announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms. Prior to joining Sutro, Dr. Gerber served as Chief Scientific Officer at Codeable Therapeutics. In connection with Dr. Gerber's appointment as Chief Scientific Officer, the Compensation Committee of Sutro's Board of Directors granted to Dr. Gerber 175,000 shares of Sutro stock options and 150,000 restricted stock units of Sutro common stock.

08:07 EDT U Power enters strategic cooperation agreement with Magnify Capital Partners - U Power announced that the Company has entered into a strategic cooperation agreement with Magnify Capital Partners, a financial/investment advisory and fund management company, to establish an investment fund. The fund will be established to provide financial support, and Magnify Capital Partners will provide industry guidance, for the Company's prospective future projects, including infrastructure construction for battery charging and battery swapping stations, both for two-wheel and four-wheel vehicles, in Portugal. The Company currently does not have any business in Portugal. The term of the Agreement is one year. Pursuant to the Agreement, both parties agree to establish a regular meeting schedule for business assessment and information exchange, and to set up a project team as the executive team of the cooperation that will be fully responsible for the development of business. Jia Li, Chief Executive Officer, and Chairman of the Board of Directors of the Company, commented, "We are excited to start the cooperation with Magnify Capital Partners, which we believe will prepare us well for business development and expansion in Portugal and other Portuguese-speaking regions. The cooperation marks our debut in this brand-new market and is expected to improve our industrial competitiveness and market influence. We look forward to seeing more progress of our business development efforts both locally and overseas while generating more value for our shareholders."

08:06 EDT scPharmaceuticals receives FDA feedback on two long-term growth initiatives - scPharmaceuticals announced that the Company has received positive feedback from the U.S. Food and Drug Administration on two key long-term growth initiatives. The Company today announced FDA feedback from a Type C meeting pertaining to the development of an 80mg/1mL auto-injector intended to provide an additional option to the on-body infusor for treatment of congestion due to fluid overload in eligible adult patients who do not require hospitalization. The Company expects that an auto-injector, if successfully developed and approved, would reduce manufacturing costs compared to the current on-body infusor and confer environmental advantages. scPharmaceuticals plans to report data from a pivotal pharmacokinetic study in first half of 2024, and, if successful, targets submitting a Supplemental New Drug Application to the FDA by the end of 2024. The Company also announced today feedback from a Type D meeting with the FDA pertaining to the potential expansion of the FUROSCIX label to include treatment of edema due to fluid overload in patients with CKD. In its feedback, the FDA confirmed that no additional clinical studies are needed to expand the indication, provided that the Company demonstrates an adequate PK and pharmacodynamic bridge to the listed drug, furosemide injection, 10 mg/mL. CKD is a progressive disease characterized by worsening renal function over time, resulting in frequent episodes of fluid overload that are treated with loop diuretics.

08:05 EDT Abbott and WeightWatchers connected app now available for diabetes patients - Abbott ( ABT) and WW International (WW), known as WeightWatchers, announced the availability of a connected app to help people living with diabetes understand how food and activity impact their glucose levels. WeightWatchers members who follow the WW Diabetes-Tailored Plan can now access their glucose data from Abbott's FreeStyle Libre, a continuous glucose monitoring system, within their WW app while being guided by the WW Diabetes-Tailored Plan. The FreeStyle Libre portfolio is a sensor-based glucose monitoring system.

08:04 EDT UpHealth subsidiary files voluntary reorganization under Chapter 11 - UpHealth announced that its subsidiary, UpHealth Holdings, has filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The Chapter 11 filing follows the September 14, 2023 decision by a trial court in New York to grant summary judgment in favor of Needham & Company in a lawsuit unrelated to the Company's operations. Sam Meckey, CEO, stated: "Following the summary judgement, we immediately initiated a comprehensive review of our options, and determined that voluntarily filing for Chapter 11 is necessary to mitigate the financial impact of the trial court's decision. We do not expect this announcement to have any impact on our operations or on the work we are doing to deliver technology-enabled services to our customers. We remain confident in the future prospects of our business, and are taking this proactive step so that we may best protect the interests of our stakeholders and achieve a fair resolution of this matter through an appeals process of the Needham judgment. We will continue to explore all possibilities while advancing the critical mission of UpHealth. In the meantime, I would like to recognize our dedicated employees, whose continued support and commitment are essential to our ability to continue our important mission and maintain our commitment to our customers and partners." UpHealth's subsidiary, UpHealth Holdings, will be filing a number of customary first day motions that, once approved, will allow the Company to continue to operate in the normal course of business without interruption to its customers, vendors and employees. The Company expects to receive Court approval for these requests and intends to pay vendors in full for all goods received and services provided after the filing date.

08:04 EDT Uber, Oracle announce new offering called 'Collect and Receive' - Oracle (ORCL) and Uber (UBER) announced "Collect and Receive," a new offering on the Oracle Retail platform connecting retailers and consumers to enhance and enrich last mile delivery. Supported by the Oracle Retail Data Store and cloud platform technologies, retailers can now link to Uber Direct, the company's white-label delivery solution, via pre-integrated APIs. This joint solution enables retailers to rebalance inventory while giving customers more choices, including same-day and scheduled delivery options, order pickup, and returns to the closest retail or postal location. The service is available today for Oracle Retail customers in the US and Canada. Learn more and schedule a demo here.

08:02 EDT Dyadic International enters development, license agreement for Dapibus - Dyadic International announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus. Under the agreement, Dyadic will receive an upfront payment of $0.6 million for product development and licensing its Dapibus platform, in addition to potential success fees, milestones, and royalties. "Today's announcement further demonstrates the growing interest and commercial potential of our Dapibus platform for use in developing and manufacturing alternative proteins for non-pharmaceutical applications. Alternative proteins are alternatives to animal proteins, which are obtained from a variety of sources and used to replace conventional animal-based proteins. The current addressable market exceeds $60 billion, which is expected to grow to over $190 billion by 2028," said Joe Hazelton, Chief Business Officer of Dyadic.

08:02 EDT Leidos awarded $7.9B U.S. Army tactical IT hardware contract - Leidos was recently awarded a next-generation prime contract to provide the U.S. Army with rapid procurement of information technology hardware solutions. The indefinite delivery, indefinite quantity contract has a base period of performance of four years with two three-year options. The contract has a maximum value of $7.9B if all options are exercised. Leidos will enhance mission readiness through the Leidos Intelligent Logistics Platform.

07:58 EDT Momentus in deal with Aarhus for transportation, orbital delivery in late 2024 - Momentus has signed a contract with Aarhus University for transportation and orbital delivery services in late 2024. Aarhus University will be flying its DISCO-II payload designed to provide climate monitoring. The university's DISCO-I payload was placed into Low-Earth Orbit during the Vigoride-6 mission that launched in April 2023. DISCO is the Danish Students CubeSat Program. "DISCO-2 will be the most ambitious student CubeSat mission in Denmark to date and students from three universities will be highly involved in all aspects of the mission," said Telescope and Satellite manager at Aarhus University and leader of the DISCO-2 mission Mads Fredslund Andersen. "With the successful launch of DISCO-1 earlier this year and DISCO-2 next year, we are looking into a very exciting period for the DISCO program." ...Momentus is a U.S. commercial space company that offers commercial satellite buses and in-space infrastructure services including in-space transportation, hosted payloads, and other in-orbit services.

07:46 EDT Danaher to provide Cepheid's tuberculosis test to the Global Fund at cost - Danaher will provide Cepheid's Xpert MTB/RIF Ultra diagnostic test cartridges for tuberculosis at Cepheid's cost of $7.97 each to the Global Fund to Fight AIDS, TB and Malaria and to less-developed countries eligible for Cepheid's Global Access Program to support greater access to high-quality TB testing. The Global Fund is the largest provider of financing and programs to combat TB globally, ensuring each year that millions of tests are distributed in countries where the need to improve access is greatest. By reducing the price of Cepheid's Xpert MTB/RIF Ultra test cartridge to $7.97, Danaher will be selling at its cost and will earn no profit. Both Cepheid and the Global Fund are members of a consortium that also includes the Stop TB Partnership, the Global Drug Facility, and USAID, which aims to increase access to essential diagnostic testing solutions in support of the global goal to end TB around the world by 2030. Cepheid's Xpert TB test was developed in partnership with FIND and the Bill and Melinda Gates Foundation. Going forward, Cepheid will validate its actual cost annually with an internationally accredited third-party assessment and adjust pricing accordingly, if necessary, so that Danaher can assure that it continues to earn no profit from these cartridge sales.

07:39 EDT Wesdome Gold Mines confirms continuity of Presqu'ile Zone - Wesdome Gold Mines announces the 2023 surface exploration drilling results from the Presqu'ile Zone located 1.3 km north-west of the Company's 100% owned Kiena Mine Complex in Val d'Or, Quebec. Recent drilling at Presqu'ile is part of an ongoing exploration program focussing on near surface gold potential along strike from Kiena that remains under explored. Drilling results from the Shawkey and Dubuisson Zones, located further to the east along strike, were released earlier this year. Ongoing drilling highlights the potential of this area to add to the existing resource base proximal to mine infrastructure and remains a priority for the Company. Highlights of recent in-fill drilling are listed below and are summarized in Table 1. Assay results for nine of thirty-two diamond drill holes planned are pending. Hole PR-23-070: 32.5 g/t over 3.0 m core length PR-2A Zone. Hole PR-23-084 : 14.0 g/t Au over 5.3 m core length PR-2 Zone. Hole PR-23-058A : 9.31 g/t Au over 4.6 m core length PR-2 Zone. Anthea Bath, President and CEO commented, "We are pleased with the recent surface drill results that confirm continuity of mineralization at Presqu'ile. The Presqu'ile Zone is just one of several zones having the potential to offer a supplementary source of mill feed near-surface or in the upper mine area for the underutilized Kiena mill. Recent drilling results from the Shawkey and Dubuisson Zones, both adjacent to the existing 33-level track drift development that extends over three kilometres east of the Kiena mine shaft, further reinforces the potential of this area. As our exploration continues and the refinement of the geologic model increases, we are confident we will identify more zones of gold mineralization accessible from 33 level, as well as additional down plunge extensions similar to the Kiena Deep Zone. Recent drilling supports the decision to proceed with the exploration ramp from surface later this year to further assess the continuity of the mineralization and test the down plunge extension of the deposit. The excavation of the ramp is expected to proceed in Q4 2023 once required permits are secured. This ramp can also be integrated with Kiena's existing underground ramp network, providing additional access to surface for ongoing operations and future mining of deposits such as Dubuisson from 33 level further to the east."

07:35 EDT Lilium marks milestone with commencement of fuselage assembly - Lilium announced that it has achieved a significant development milestone with the commencement of fuselage assembly for the Lilium Jet, which remains on track for expected first manned flight planned in late 2024. Start of fuselage assembly serves as another tangible manifestation of Lilium's strategic roadmap, demonstrating Lilium's ability to progress from vision to execution. This is the first of seven fuselages for the seven aircraft Lilium will use to achieve type-certification of the Lilium Jet. The fuselage was developed in collaboration with, and is being built by, tier one aerospace supplier and strategic partner Aciturri at its facilities in Valladolid, Spain. The fuselage is planned for delivery to Lilium facilities in Wessling, Germany in the fourth quarter 2023, prior to planned start of assembly of the first Lilium Jet by year end. Klaus Roewe, CEO of Lilium, commented: "This phase is more than just a technical step - it's a clear signal to all Lilium stakeholders of our commitment to making regional air mobility more efficient, enjoyable, and sustainable. As we assemble the fuselage, we are also crafting a transformative flying experience while upholding our promise of unparalleled efficiency, comfort, and safety."

07:34 EDT PyroGenesis signs order with aerospace firm for metal powder for 3D printing - PyroGenesis Canada announces that the Company has received a small signed order from a global aerospace firm. This order pertains to PyroGenesis' plasma atomized titanium metal powders designed for 3D printing and is intended for one of the Client's ongoing internal research and development programs. Unlike the recently announced contract for fine powder, this new order is for "coarse cut" metal powder, typically considered a by-product from the production runs that produce fine powders ranging from 20-45 microns in size. "The significance of this order is the particle size distribution that has been requested", said P. Peter Pascali, CEO and President of PyroGenesis. "The PSD for this order is for our coarse cut titanium powder, in this case for powder between 45-150 microns, which we have been producing over the past year as we build our stock inventory. This contract recognizes what we believe is the superior overall quality of our powder and establishes a market for a larger percentage of our powder output, thereby improving our overall returns substantially."

07:20 EDT Sapiens selected by AAFMAA to modernize customer acquisition processes - Sapiens announced that the American Armed Forces Mutual Aid Association - AAFMAA -, a non-profit financial solutions provider for military families and Veterans, has selected Sapiens' Pro Series Customer Acquisition SaaS solution, consisting of Sapiens' ApplicationPro, IllustrationPro, UnderwritingPro, and Intelligence, as a part of its legacy modernization and automation initiative. AAFMAA is a new Sapiens customer whose implementation of the Sapiens Pro Series Customer Acquisition solution should be completed during Q2 2024.

07:15 EDT Ninja Labs, Vivior unveil VIVIOR 4SIGHT gamer wellness platform - Ninja Labs, a GameSquare initiative, and Vivior announced the launch of the beta version of Vivior 4SIGHT, a gamer wellness platform aimed at enhancing gamers' overall well-being and optimizing their gaming performance. The companies said, "The platform is the first major project to come out of Ninja Labs, GameSquare's innovation initiative led by famed streamer and newly appointed GameSquare Chief Innovation Officer, Tyler "Ninja" Blevins. Vivior 4SIGHT marks a pioneering step forward in gaming and health-centric technology, allowing gamers to seamlessly integrate their wellness wearable devices and apps. By prioritizing health and fitness, gamers can now unlock rewards and prizes simply by maintaining an active and healthy lifestyle while also participating in engaging wellness missions and challenges."

07:12 EDT AutoZone reports Q4 total company SSS up 4.5% - Reports Q4 international SSS up 34.1%.

07:08 EDT Nasdaq's Capital Access Platforms launches sustainability offerings - Nasdaq announced its Capital Access Platforms division has launched two new offerings designed to help corporates and investors better streamline their sustainability and impact investing journeys. Nasdaq Metrio is a SaaS-based, end-to-end platform that will help corporates to better collect, measure and report sustainability data. Nasdaq eVestment ESG Analytics will unlock greater transparency for the global institutional market so investors can make better data-driven impact investment decisions. "We are committed to meeting current and future corporate and investor needs to help clients unlock return on investment for their sustainability initiatives and impact investing strategies," said Nelson Griggs, President of Capital Access Platforms, Nasdaq. "Our clients look to us to help inform the development of market-based, demand-driven solutions to better navigate the rapidly evolving and impact investing ecosystem. It's an exciting time for our Capital Access Platforms division, just nine months into Nasdaq's enhanced corporate structure, and these offerings showcase our unique position as a bridge between corporates and investors."

07:08 EDT Mobilicom secures initial order from defense contractor in Europe - Mobilicom announced an initial purchase order for two of its products from a new customer, one of the largest defense contractors in Europe. "Our new customer is one of the top names in European defense contracting. Europe is an evolving market in which we are seeing increasing traction with our end-to-end offering. NATO countries have increased their defense budgets significantly in response to the Ukraine-Russia conflict, where drones have proven to be a game-changer in the war. The demand for and use of drones is expected to rise sharply in the next few years and Mobilicom is well positioned as a leading provider of field-proven, cybersecure technologies," stated Mobilicom CEO Oren Elkayam.

07:07 EDT PolyPid successfully completes manufacturing process validation for D-PLEX - PolyPid announced the successful completion of the production of three process validation batches of D-PLEX100 which have started stability program. This successful production process validation completes a substantial requirement toward the Company's planned submission of D-PLEX100 New Drug Application and Marketing Authorization Application (MAA) regulatory filings. "The successful validation of the production process at commercial scale is the result of a significant facility expansion and scale-up that more than tripled the Company's capacity to manufacture D-PLEX100 for the U.S., EU and global markets," stated Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "Our in-house state-of-the-art GMP sterile production facility provides us with full control of D-PLEX100 manufacturing from clinical stage to commercial supply and serves as a key competitive advantage going forward. Importantly, we have now evolved into a fully-integrated biopharmaceutical company." PolyPid's ongoing Phase 3 SHIELD II trial of D-PLEX100 for the prevention of surgical site infections is currently recruiting patients undergoing open abdominal colorectal surgery with large incisions. Top-line results are expected in mid-2024.

07:05 EDT Applied Optoelectronics files patent infringement suit against Molex - Applied Optoelectronics has filed a complaint for patent infringement against Molex. The complaint, filed yesterday, September 18, 2023 in the U.S. District Court for the Northern District of California, alleges that at least the Molex 100G QSFP28 PSM4 optical transceiver module infringes two of Applied Optoelectronic's patents: U.S. Patent No. 9,523,826, entitled "Pluggable Optical Transceiver Module," which was issued on December 20, 2016, and U.S. Patent No. 10,466,432, entitled "High Speed Optical Transceiver Module," which was issued on November 5, 2019. In the complaint filed yesterday, AOI is seeking monetary damages from Molex and a permanent injunction.

07:04 EDT Worksport signs supply agreement, estimated to make $16M in annual sales - Worksport announces it has secured a long-term supply agreement with an established, leading automotive aftermarket reseller in the U.S. Under this agreement, Worksport is on track to earn an estimated $16,000,000 USD in annual sales of its advanced hard-folding and soft-folding covers, from this single customer. While estimated sales of $16 Million USD are based on the customer's forecast on an annualized basis, this estimate does not include the customer's expectations of year-over-year growth in sales. The agreement resulted from samples that were provided to and approved by this customer previously. This significant step follows the recent start of manufacturing at Worksport's Western New York-based facility after receiving a robust $1.6 million order for its hard-folding covers and an additional $720,000 order for the soft-folding versions, both from the same customer. Steven Rossi, CEO of Worksport, expressed with conviction, "Our eyes are set on growth, cash flow positivity, and earnings in the very near future, along with getting our high-quality product into the hands of pickup truck owners."

07:03 EDT Sabre expands relationship with Virgin Australia - Sabre has strengthened and expanded its relationship with Virgin Australia to allow the carrier to deliver improved retailing capability while supporting its growth objectives. Through Sabre's scalable, intelligent solutions, Virgin Australia will be able to create fares and offers alongside a future-focused distribution strategy to get those offers in front of the right buyers and travelers. Under the new strategic agreement, the carrier will deploy Sabre Air Price and Sabre Ancillary - two intelligent retailing solutions from its Retail Intelligence suite designed to help airlines increase traveler satisfaction and improve revenue management optimization. Powered by Sabre Travel, these sophisticated solutions will enable Virgin Australia to use flight and market insights combined with advanced machine-learning models to move from static pricing rules to intelligent real-time airfare and ancillary offers. Virgin Australia and Sabre have also renewed their multi-year distribution agreement to ensure Sabre-connected travel agencies can continue to shop, book and service Virgin Australia's air and ancillary offers with speed and scalability.

07:03 EDT Boston Scientific signs agreement to acquire Relievant Medsystems - Boston Scientific has entered into a definitive agreement to acquire Relievant Medsystems, a privately held medical technology company that has developed and commercialized the Intracept Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850M and undisclosed additional contingent payments based on sales performance over the next three years. The Intracept system is a minimally invasive, implant-free outpatient procedure. The therapy uses targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain and is designed to improve function and provide long-term relief. Boston Scientific expects to close the transaction in the first half of 2024, subject to satisfaction of customary closing conditions. Relievant is expected to generate sales in excess of $70M in 2023 and to deliver year-over-year growth in excess of 50% in 2024. On an adjusted basis, the transaction is expected to be immaterial to adjusted EPS in 2024, slightly accretive in 2025, and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges.

07:02 EDT IM Cannabis announces departure of CFO Itay Vago - IM Cannabis announced that Itay Vago, the company's CFO, has decided to leave the company for personal reasons. Current plans call for Vago to continue to serve as CFO until the publication of the Q3 2023 results. The company has commenced a formal search for a new CFO and Vago is anticipated to support the transition through the publication of the Q3 2023 results.

06:57 EDT AutoZone reports inventory up 2.2% y/y - The company's inventory increased 2.2% over the same period last year driven by new store growth. Net inventory, defined as merchandise inventories less accounts payable, on a per store basis, was negative $201 thousand versus negative $240 thousand last year and negative $215 thousand last quarter.

06:52 EDT Hut 8 Mining provides update on USBTC combination - Hut 8 Mining continues to make progress on the proposed business combination pursuant to which Hut 8 and U.S. Data Mining Group, Inc. dba US Bitcoin Corp, or USBTC, will combine in an all-stock merger of equals. The combined company will be named "Hut 8 Corp." and will be a U.S.-domiciled entity. Completion of the transaction remains subject to the remaining regulatory approvals, shareholder approval, and other customary closing conditions of the transaction.

06:47 EDT Bright Health makes progress towards ACA insurance business wind-down - Bright Health Group announced it continues to make progress on the wind-down of its ACA insurance business. The company has made significant progress paying down its medical claims obligations and is on track with prior forecasts. As of the end of August, the company believes that its claims runout is over 98% complete. Bright Health's final risk adjustment obligations across its ACA insurance business markets were consistent with expectations at year-end 2022 and the end of the Second Quarter 2023. As of 9/19, Bright Health has paid $1.5B to the Centers for Medicare & Medicaid Services, which represents 80% of its final ACA insurance business risk adjustment obligations. Bright Health also announced that its insurance subsidiaries in Colorado, Florida, Illinois and Texas have entered into repayment agreements for a principal amount of $380M with CMS with respect to the unpaid amount of the risk adjustment obligations. The principal amount of the repayment agreements is due in 18 months and bears interest at 11.5%. Exclusive of its obligations under the repayment agreements, Bright Health expects to have approximately $105M in excess cash surplus in Colorado, Florida, Illinois and Texas, after reserving for expected medical costs and other anticipated wind-down expenses. The company further expects to recover approximately $115M in regulatory capital surplus in its other markets, subject to final claims runout and regulatory approval. Together, this results in an estimated net risk adjustment obligation of $160M, before interest costs, after applying estimated excess cash reserves and regulatory capital surplus against the outstanding principal amount under the repayment agreements. The company intends to use a portion of the proceeds from the pending sale of its California Medicare Advantage business to pay any remaining amounts due under the repayment agreements.

06:22 EDT GSK announces European Commission authorized ViiV Healthcare's Apretude - GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, announced that the European Commission has authorised Apretude for HIV prevention. Cabotegravir is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. Cabotegravir LA injectable and tablets for PrEP is the first and only HIV prevention option approved in the European Union that reduces the number of doses needed for effective HIV prevention from 365 daily pills to as few as six injections per year. This approval is supported by data from two international phase IIb/III multicentre, randomised, double-blind, active controlled studies, HPTN 083 and HPTN 084. The studies demonstrated that cabotegravir LA for PrEP was superior to daily oral FTC/TDF tablets, with clinical trial participants given cabotegravir LA for PrEP experiencing a 69% lower rate of HIV acquisition compared to FTC/TDF tablets in HPTN 083, and a 90% lower rate of HIV acquisition compared to FTC/TDF tablets in HPTN 084.

06:11 EDT Fortis announces new $25B five year capital outlook - Fortis released its 2024-2028 outlook, including a 2024-2028 capital plan of $25.0B, representing 6.3% rate base growth; up $2.7B from its 2023-2027 five-year plan; growth largely driven by investments in transmission in the U.S. Midwest and resource transition plan in Arizona; a Q4 dividend increase of 4.4%; and an annual dividend growth guidance of 4-6% extended to 2028. The corporation announced its new 2024-2028 capital plan of $25.0B, the largest in the corporation's history, and $2.7B higher than the previous five-year plan. The increase is supported by the Inflation Reduction Act of 2022, and largely reflects regional transmission projects. Approximately 27% of the five-year capital plan is allocated to cleaner energy investments focused on connecting renewables to the grid, renewable and storage investments in Arizona and the Caribbean, and cleaner fuel solutions in British Columbia. The corporation's $25.0B five-year capital plan is expected to increase midyear rate base from $36.8B in 2023 to $49.4B by 2028, translating into a five-year compound annual growth rate of 6.3% on a constant foreign exchange basis. The five-year capital plan is expected to be funded primarily by cash from operations and regulated debt. Common equity proceeds are expected to be sourced from the corporation's dividend reinvestment plan and an at-the-market common equity program.

06:04 EDT Hywin Holdings acquires land in Hainan Boao for health management center - Hywin Holdings has won a bid to acquire the land use rights of a parcel of land with a total site area of 56,449.39 square meters and the above-ground construction in progress, situated at Boao Lecheng International Medical and Tourism Pilot Zone, Hainan Province, the People's Republic of China. The Real Property will be used to build Hywin's first integrated health management center pilot project. Boao Lecheng is a pilot zone in China focusing on developing medical technology, medical services and medical tourism, and promoting clinical research in advanced fields. Hywin received confirmation that the company has won a bid to acquire the Real Property through judicial auction at a consideration of approximately RMB129.2M. Hywin has already paid a bid security deposit of RMB10.0M, which shall form part of the consideration. The consideration shall be settled by the company in cash.

05:53 EDT Citi launches Citi Token Services for institutional clients - Citi Treasury and Trade Solutions announced Monday the creation and piloting of Citi Token Services for cash management and trade finance. The service uses blockchain and smart contract technologies to deliver digital asset solutions for institutional clients. Citi Token Services will integrate tokenized deposits and smart contracts into Citi's global network, upgrading core cash management and trade finance capabilities. Institutional clients have a need for 'always-on', programmable financial services and Citi Token Services will provide cross-border payments, liquidity, and automated trade finance solutions on a 24/7 basis. Shahmir Khaliq, Global Head of Services, said, "Digital asset technologies have the potential to upgrade the regulated financial system by applying new technologies to existing legal instruments and well-established regulatory frameworks. The development of Citi Token Services is part of our journey to deliver real-time, always-on, next generation transaction banking services to our institutional clients. This development goes hand-in-hand with our industry leading work on the Regulated Liability Network to create interoperable digital asset solutions on a multi-bank basis."

05:16 EDT Pfizer announces EC approval for Litfulo - Pfizer announced that the European Commission, or EC, has granted marketing authorization for Litfulo to treat adults and adolescents 12 years of age and older with severe alopecia areata. Litfulo, a once-daily oral capsule, is the first medicine authorized by the EC to treat individuals as young as 12 years of age with severe alopecia areata. Litfulo is also the first and only treatment to selectively inhibit Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma family of kinases.

05:08 EDT Rocket Lab reports issue during 41st mission, experiences loss of mission - Rocket Lab experienced an issue during the launch of the company's 41st mission. Following lift-off from Launch Complex 1, the rocket completed a first stage burn and stage separation as planned, before an issue was experienced at around T+ 2 minutes and 30 seconds into flight, resulting in the end of the mission. The company said, "We are deeply sorry to our partners Capella Space for the loss of the mission. We are working closely with the FAA and supporting agencies as the investigation into the root cause commences. The Electron rocket has previously delivered 171 satellites to orbit across 37 successful orbital missions. We will identify the issue swiftly and implement corrective actions and return to the pad shortly. Our next mission, currently scheduled before the end of the third quarter, will be postponed while we implement corrective actions. We anticipate providing revised third quarter revenue guidance in the coming days."